|
See related Uromitexan inj information |
|
|
|
Manufacturer |
Baxter Healthcare |
|
Distributor |
Hong Kong: Baxter Healthcare/Macau: Firma Chun Cheong |
|
Contents |
Mesna |
|
Indications |
Prevention of urothelial toxicity due to oxazaphosphorines. |
|
Dosage |
Adult 20% of oxazaphosphorine dose at time 0 (time of oxazaphosphorine inj) & then at 4 & 8 hr IV. |
|
Special Precautions |
Protective effect applies only to the urinary tract. Pregnancy & lactation. |
|
Adverse Drug Reactions |
GI effects, headache, pain in limb, decrease BP, tachycardia, skin reactions, exhaustion & weakness.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
ATC Classification |
V03AF01 - mesna ; Belongs to the class of detoxifying agents used in antineoplastic treatment. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Uromitexan injection |
|
Uromitexan 100 mg/1 mL x 4 mL x 15's |
|
|
|
Manufacturer: |
Baxter Healthcare |
|
Distributor: |
Hong Kong: Baxter Healthcare
Macau: Firma Chun Cheong
|
|
|
|
